A New Antiviral Agent for Influenza — Is There a Clinical Niche?
- 25 September 1997
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (13) , 927-928
- https://doi.org/10.1056/nejm199709253371310
Abstract
Zanamivir, a new antiviral agent for influenza, is a potent inhibitor of the viral neuraminidase of types A and B influenzaviruses.1 The design of zanamivir was based on the three-dimensional structure of the neuraminidase, a structural unit on the surface of the viral particle. In this issue of the Journal, Hayden et al. report that treatment of community-acquired type A and B influenza with zanamivir shortened the duration of major symptoms by about one day in the study group as a whole and about three days in the sicker patients if the drug was started early.2 Zanamivir probably interrupts an . . .Keywords
This publication has 5 references indexed in Scilit:
- Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus InfectionsNew England Journal of Medicine, 1997
- Influenza Neuraminidase Inhibitors Possessing a Novel Hydrophobic Interaction in the Enzyme Active Site: Design, Synthesis, and Structural Analysis of Carbocyclic Sialic Acid Analogues with Potent Anti-Influenza ActivityJournal of the American Chemical Society, 1997
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitroAntimicrobial Agents and Chemotherapy, 1993
- Influenza: Its Control in Persons and PopulationsThe Journal of Infectious Diseases, 1986
- SERIOUS MORBIDITY AND MORTALITY ASSOCIATED WITH INFLUENZA EPIDEMICSEpidemiologic Reviews, 1982